Compugen (CGEN)
(Delayed Data from NSDQ)
$1.92 USD
+0.02 (1.05%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $1.91 -0.01 (-0.52%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.92 USD
+0.02 (1.05%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $1.91 -0.01 (-0.52%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
Ensign Group (ENSG) expects annual revenues for 2022 in the band of $2.93-$2.98 billion, whose midpoint signals a 12.4% rise from the 2021 reported figure.
Compugen (CGEN) Stock Up on Bristol Myers' $20M Investment
by Zacks Equity Research
Compugen (CGEN) announces an expansion of its collaboration agreement with Bristol Myers Squibb and a $20 million equity investment by the latter.
Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?
by Zacks Equity Research
On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.
Insight Enterprises' (NSIT) Q3 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Insight Enterprises' (NSIT) Q3 performance benefits from acquisition of PCM amid sluggish demand from Asia Pacific and EMEA.
What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.
What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.
What's in Store for Selecta (SELB) This Earnings Season?
by Zacks Equity Research
In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.
Is the Options Market Predicting a Spike in Compugen (CGEN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.
How Compugen (CGEN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for May 8th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 8th.
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
What Makes Compugen (CGEN) a New Strong Buy Stock
by Zacks Equity Research
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Top Ranked Momentum Stocks to Buy for April 30th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th.
Company News for Mar 10, 2020
by Zacks Equity Research
Companies In The News Are: COCP, CGEN, AAPL, NINE
5 Biotech Stocks That Have More Than Doubled This Year
by Ekta Bagri
The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
5 Biotech Stocks Up More Than 100% This Year So Far
by Indrajit Bandyopadhyay
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) is a Great Choice
by Zacks Equity Research
Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compugen (CGEN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MyoKardia Begins Dosing in Phase I Study on Heart Candidate
by Zacks Equity Research
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
by Zacks Equity Research
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
Mallinckrodt Enrolls First Patient in Liver Disease Study
by Zacks Equity Research
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut
by Zacks Equity Research
AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.
Compugen (CGEN) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Compugen (CGEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.